Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRING: Antiplatelet Therapy in ICH Pilot
NCT04522102Phase 3Completed
- Sponsor
- The George Institute for Global Health
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in vascular disease (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Regulatory approvals at 6 months. Started Sep 2021; status: completed.
02
Conditions
vascular disease
Beyond the preview
Go deeper on NCT04522102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522102.